BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 11, 2026
Home » Topics » Medical technology

Medical technology
Medical technology RSS Feed RSS

Patent watch: Antares Pharma gains patent for auto injector technology

Oct. 28, 2013

International report: Boston Scientific's Alair system approved In China

Oct. 28, 2013

Could crowdfunding be the savior of early-stage med-tech?

Oct. 25, 2013
By Omar Ford
It's no secret that it's harder and harder for med-tech firms to receive early stage funding. I think my last six blogs have been about that topic alone. But while its true that some venture capital firms are looking to invest in med-tech companies at a later stage in the development cycle, some firms are getting fairly creative and are going toward crowdfunding. Last  week, I wrote a story about Amulyte (Markham, Ontario), a company that has developed an emergency response device that helps seniors live on their own terms, and its move toward the crowdfunding model. The company partnered...
Read More

People in the News

Oct. 25, 2013

Product Briefs

Oct. 25, 2013

MDD's Diagnostic Extra

Oct. 25, 2013

HART pushes forward to gain FDA nod for trachea transplant system

Oct. 25, 2013
By Omar Ford

Washington roundup: NICE suggests hip revision set point be cut to 5% at 10 years

Oct. 25, 2013
By Mark McCarty

Israel BrainTech Conference: Shimon Peres attributes Israel's success to never being satisfied

Oct. 25, 2013
By Jonathan Goldstein
TEL AVIV — The First Israel BrainTech Conference (IBT) being held here, is the brainchild of Israel's President Shimon Peres. When interviewed, the president tried to explain the secret of the small state's technological successes. "Well," he explained, "you'll find something very common in the Israeli character – we are never satisfied." That lack of satisfaction or complacency, he explained, was the key to getting people to think out of their comfort zone, and being prepared to make strides in directions that they might not have made otherwise. Israelis are good at these bold moves.
Read More

Deals roundup: McKesson to buy Celesio for $8.3 billion, including debt

Oct. 25, 2013
By Amanda Pedersen
Previous 1 2 … 3401 3402 3403 3404 3405 3406 3407 3408 3409 … 10246 10247 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 8, 2026.
  • Rendering of a key measles protein targeted by neutralizing human antibodies

    First measles treatment advances as vaccination rates drop

    BioWorld
    Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
  • Infensa Bioscience identifies new ASIC blockers

    BioWorld Science
    Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
  • Close up of bow of cruise ship

    Hantavirus is ‘sentinel’ more than acute pandemic threat

    BioWorld
    News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
  • Neurology illustration

    Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst

    BioWorld
    Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing